6 Undervalued Biotechnology & Medical Research Stocks for Monday, January 01
Discover the top 6 undervalued Biotechnology & Medical Research stocks for Monday, January 01 based on AAII’s Stock Grades.Eunice Kim
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Commentary & Analysis
7 Undervalued Biotechnology & Medical Research Stocks for Friday, November 17
Discover the top 7 undervalued Biotechnology & Medical Research stocks for Friday, November 17 based on AAII’s Stock Grades.Eunice Kim
Why Revelation Biosciences Inc’s (REVB) Stock Is Up 2946.70%
As of Wednesday, February 01, Revelation Biosciences Inc’s REVB share price has surged by 2946.70%, which has investors questioning if this is right time to sell.Jack Gilleland
Is Revelation Biosciences Inc (REVB) Stock a Good Investment?
Learn more about Revelation Biosciences Inc's (REVB) stock grades for Momentum, Growth and Estimate Revisions and determine whether this Biotechnology & Medical Research stock meets your investment needs.Jack Gilleland
Financial Summary
| Share Statistics | REVB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2.3 | $223.5 | 2% |
|
| Shares Out (Mil) | 0.5 | 53.4 | 3% |
|
| Institutional Ownership | 11.4% | 92.9% | 7% |
|
| Float (Mil) | 0.4 | 40.4 | 1% |
|
| Beta | -0.06 | 0.96 | 5% |
|
| Avg Daily Volume (000s) | 30 | 463 | 25% |
|
| Price Change (52-week) |
(88.4%) | 45.9% | 6% |
|
| Growth | REVB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (28.9%) | (10.1%) | 14% |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($6.160) | ($36.295) | ($20.230) | |
| Month Ago EPS | ($6.160) | ($36.295) | ($20.230) | |
| # Rev Up | na | 1 | 1 | |
| # Rev Down | na | 0 | 0 | |
| Three Months Ago EPS | ($5.635) | ($34.965) | ($19.425) | |
| Year/Year Chg | 1.4% | (78.3%) | (85.9%) | |
| Financials | REVB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($11) | ($44) | 29% |
|
| EPS (TTM) | ($58.179) | ($1.600) | 1% |
|
| Operating Cash Flow (TTM) (Mil) | ($9) | ($33) | 21% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 15% |
|
| Enterprise Value (Q1) (Mil) | ($9) | $173 | 2% |
|
| Valuation | REVB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.22 | 2.08 | 4% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | REVB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (120.2%) | (47.0%) | 4% |
|
| ROE | (154.8%) | (52.7%) | 6% |
|
| Liabilities to Assets | 19.5% | 29.6% | 13% |
|
| F-Score | 2 | 2 | na |
|
Revelation Biosciences, Inc. did not pass any screens on 11/2/2026.
